Probenecid

Generic Name: Probenecid

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₉NO_₄S

CAS Number: 57-66-9

Unique Ingredient Identifier: PO572Z7917

Background: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.

Indication: For the reduction of serum uric acid concentrations in chronic gouty arthritis and tophaceous gout in patients with frequent disabling gout attacks. Has also been effectively used to promote uric acid excretion in hyperuricemia secondary to the administration of thiazide and related diuretics.

Associated Conditions: Bacterial Infections, Chronic Gouty Arthritis, Elevated Serum Uric Acid, Gout Chronic, Hyperuricemia, Infection

Associated Therapies: -

Clinical Trials

A Study of Baricitinib and Probenecid in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Baricitinib
Drug: Probenecid

First Posted Date: 2013-09-09

Last Posted Date: 2017-06-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 18

Registration Number: NCT01937026

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom

Intravesical Cidofovir for Hemorrhagic Cystitis

Phase 1

Completed

Conditions: Blood And Marrow Transplantation

Interventions: Drug: Cidofovir
Drug: Probenecid

First Posted Date: 2013-03-22

Last Posted Date: 2016-12-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT01816646

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and Probenecid

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Probenecid
Drug: Empagliflozin (BI 10773)
Drug: Empagliflozin
Drug: Rifampicin

First Posted Date: 2012-07-06

Last Posted Date: 2014-07-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT01634100

Locations: 🇩🇪
1245.83.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function

Phase 3

Completed

Conditions: Renal Function
Overweight
Obesity
Endothelial Function
Blood Pressure

Interventions: Drug: Vitamin D ergocalciferol
Drug: Allopurinol
Drug: Placebo
Drug: Probenecid

First Posted Date: 2011-03-22

Last Posted Date: 2017-06-29

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 242

Registration Number: NCT01320722

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Evaluation of Renal Drug Transport in Healthy Volunteers

Not Applicable

Completed

Conditions: Kidney Disease

Interventions: Drug: probenecid

First Posted Date: 2008-06-04

Last Posted Date: 2021-05-11

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 10

Registration Number: NCT00690014

Locations: 🇺🇸
University of Maryland GCRC, Baltimore, Maryland, United States

Pharmacologic Study of Oseltamivir in Healthy Volunteers

Phase 1

Completed

Conditions: Avian Influenza A Virus

First Posted Date: 2007-02-23

Last Posted Date: 2009-07-28

Lead Sponsor: Mahidol University

Target Recruit Count: 21

Registration Number: NCT00439530

Locations: 🇹🇭
Bangkok Hospital for Tropical Diseases Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

Evaluation of Alternative Oseltamivir (Tamiflu) Dosing Strategies.

Phase 4

Completed

Conditions: Influenza

Interventions: Drug: Oseltamivir
Drug: Probenecid

First Posted Date: 2006-03-17

Last Posted Date: 2009-09-23

Lead Sponsor: US Department of Veterans Affairs

Target Recruit Count: 48

Registration Number: NCT00304434

Locations: 🇺🇸
VA Palo Alto Health Care System, Palo Alto, California, United States

Primary Prevention of Hypertension in Obese Adolescents

Phase 2

Completed

Conditions: Obesity
Pre-Hypertension
Hyperuricemia

Interventions: Drug: Placebo
Drug: Allopurinol
Drug: Probenecid

First Posted Date: 2006-02-07

Last Posted Date: 2017-09-14

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 60

Registration Number: NCT00288158

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States

10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00024245

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS

Not Applicable

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Gilead Sciences

Target Recruit Count: 100

Registration Number: NCT00002142

Locations: 🇺🇸
Besselaar Associates, Princeton, New Jersey, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy